Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative

Abstract

Background Hereditary cancer panels (HCPs), testing for multiple genes and syndromes, are rapidly transforming cancer risk assessment but are controversial and lack formal insurance coverage. We aimed to identify payers’ perspectives on barriers to HCP coverage and opportunities to address them. Comprehensive cancer risk assessment is highly relevant to the Precision Medicine Initiative (PMI), and payers’ considerations could inform PMI’s efforts. We describe our findings and discuss them in the context of PMI priorities. Methods We conducted semi-structured interviews with 11 major US payers, covering >160 million lives. We used the framework approach of qualitative research to design, conduct, and analyze interviews, and used simple frequencies to further describe findings. Results Barriers to HCP coverage included poor fit with coverage frameworks (100%); insufficient evidence (100%); departure from pedigree/family history–based testing toward genetic screening (91%); lacking rigor in the HCP hybrid research/clinical setting (82%); and patient transparency and involvement concerns (82%). Addressing barriers requires refining HCP-indicated populations (82%); developing evidence of actionability (82%) and pathogenicity/penetrance (64%); creating infrastructure and standards for informing and recontacting patients (45%); separating research from clinical use in the hybrid clinical-research setting (44%); and adjusting coverage frameworks (18%). Conclusions Leveraging opportunities suggested by payers to address HCP coverage barriers is essential to ensure patients’ access to evolving HCPs. Our findings inform 3 areas of the PMI: addressing insurance coverage to secure access to future PMI discoveries; incorporating payers’ evidentiary requirements into PMI’s research agenda; and leveraging payers’ recommendations and experience to keep patients informed and involved.

Insurance coverage does not predict outcomes of genetic testing: The search for meaning in payer decisions for germline cancer tests

“…The results of hereditary cancer genetic testing inform cancer screening recommendations and surgical considerations, and multigene germline cancer tests can identify hereditary cancer syndromes that would not be found on a targeted single gene test. However, payer identified barriers to multigene hereditary cancer testing coverage remain, including insufficient evidence, lack of rigor in test design, and the departure from diagnostic testing to genetic screening (Trosman et al, ).…”

Genetic testing in steroid-resistant nephrotic syndrome: why, who, when and how?

“…As part of the genetic counselling process, these issues should be discussed with affected families and informed consent obtained prior to genetic testing. A thorough discussion regarding the barriers to genetic testing in public health is beyond the scope of this review, but readers are directed to several useful articles for further information [100][101][102][103][104].…”

Genetic Testing in a Population-Based Sample of Breast and Ovarian Cancer Survivors from the REACH Randomized Trial: Cost Barriers and Moderators of Counseling Mode

“…These concerns are compounded by the uncertain future of the Affordable Care Act, the repeal of which would disparately affect subgroups of the population with known disparities accessing and utilizing genetic services and associated preventative services (16,41). Yet, a priority of the national Precision Medicine Initiative is to address insurance coverage to enable access to genomic discoveries and guideline-concordant genetic care delivery (42). …”